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Morphological changes and Immunohistochemical expression 
of RAGe and its Ligands in the sciatic nerve of Hyperglycemic 
pig (Sus Scrofa)
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Ananthakrishnan1, nosirudeen Quadri1, shi Du Yan1, ravichandran ramasamy1, Ann Marie schmidt1 
and Matthew s. geddis1,3
1Division of surgical science, columbia University Medical center, new York, nY, 10032, UsA. 2Division of cardiology, 
columbia University Medical center, new York, nY, 10032, UsA. 3Department of science, BMcc-city University of  
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Abstract: The aim of our project was to study the effect of streptozotocin (STZ)—induced hyperglycemia on sciatic nerve  morphology, 
blood plasma markers and immunohistochemical expression of RAGE (the Receptor for Advanced Glycation End-products), and its 
ligands—S100B and Carboxymethyl Lysine (CML)-advanced glycation endproduct (AGE) in the laboratory pig. Six months after 
STZ—injections, blood plasma measurements, morphometric analysis of sciatic nerve fiber density, immunofluorescent distribution of 
potential molecular neuropathy contributors, ELISA measurement of plasma AGE level and HPLC analysis of sciatic nerve levels of 
one of the pre-AGE and the glycolysis intermediate products—methyl-glyoxal (MG) were performed. The results of our study revealed 
that STZ—injected animals displayed elevated levels of plasma glucose, gamma glutamyl transferase (GGT) and triglycerides. The 
sciatic nerve of STZ-injected pigs revealed significantly lower numbers of small-diameter myelinated fibers, higher immunoreactivity 
for RAGE and S100B and increased levels of MG as compared to control animals. Our results correspond to clinical findings in human 
patients with hyperglycemia/diabetes-evoked peripheral neuropathy and suggest that the domestic pig may be a suitable large animal 
model for the study of mechanisms underlying hyperglycemia-induced neurological complications in the peripheral nerve and may 
serve as a relevant model for the pre-clinical assessment of candidate drugs in neuropathy.
Keywords: pig, sciatic nerve, RAGE, AGE, S100B, CML
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Introduction
Metabolic and morphological changes in  peripheral 
nerves are the most common nervous system 
 complications in patients with diabetes, often  leading to 
the development of a diabetic  polyneuropathy (DPN), 
predominately affecting sensory and  autonomic 
 function of peripheral nerves.1–3 The  molecular 
mechanisms underlying the pathogenesis of these 
diabetes related changes are not yet fully  understood, 
but lack of neurotrophic support,4  oxidative stress, 
activation of Protein Kinase C (PKC) pathway and 
enhanced  protein glycation leading to accumulation 
of Advanced Glycation End-products (AGEs)5–7 are 
among the major causes of neuronal dysfunction. 
AGEs, among which carboxymethyllysine (CML)—
AGE group is most common, are heterogeneous 
class of molecules modifying cellular function by an 
array of distinct mechanisms, including ligation and 
 activation of the signal transduction receptor, RAGE 
(Receptor for Advanced End-Glycation products).7 
Extensive studies on RAGE and its function in hyper-
glycemia/diabetes conducted in STZ-induced type 1 
diabetes small animal models have shown that RAGE 
is upregulated in diabetic tissues such as heart, retina 
and peripheral nerve, affecting the function of these 
organs and subsequently leading to the development 
of atherosclerosis and peripheral neuro-,  retino- 
and nephropathy.8,9 Furthermore, it has been shown 
that the activation of RAGE by one of its ligands, 
S100B, a calcium binding protein and glial/Schwann 
cell marker, in dorsal root ganglion (DRG) cultures 
increases cellular oxidative stress, resulting in sensory 
neuron injury, neuronal apoptosis and nerve dysfunc-
tion, factors likely contributing to the development 
of peripheral neuropathy.10 Additionally, it has been 
noted that the expression of S100B is elevated in 
neurodegenerative disorders and acute brain injuries, 
making this protein a potential biomarker and possible 
modulator of nervous system injury.11,12 In our study, 
we have focused on establishing the morphological 
and molecular evidence of peripheral nervous system 
diabetic complications in the pig, taking advantage of 
its close physiological resemblance with the human 
organism.13
Particularly in the field of diabetes, the pig 
has gained considerable interest, as its metabolic, 
 biochemical and pathophysiological responses to the 
disease mimic in part those observed in humans.14,15 
It has been shown that blood supply of the porcine 
pancreas is similar to that of human pancreas and 
the number of beta-cells is within similar range as 
observed in humans making in a valuable model for 
the study of diabetes. The most stable and commonly 
accepted pig model of diabetes is STZ-induced type 1 
diabetes (diabetes mellitus),14,15 where glucose metab-
olism and insulin secretion remain at the very similar 
level as in human diabetic patients. To date, the type 1 
STZ-induced hyperglycemic/diabetic pig model has 
been predominately validated in studies of the cardio-
vascular complications of the disease16–18 while neu-
ronal complications in this model are unclear. Thus, 
the aim of this paper is to extend the body of research 
in this, latter, area as well as provide novel data on 
distribution of RAGE and its binding partners in 
peripheral nervous system in the hyperglycemic pig.
Materials and Methods
Animals
Twelve juvenile castrated male Yorkshire pigs, 
 weighing from 17.1 kg to 23.2 kg, (ABI, Inc. 
 Danboro, PA, USA) were used in this study. The pigs 
were divided into two groups—six diabetic and six 
 control—and were  individually housed in enriched 
environment cages. Prior to the  experiment  initiation, 
the pigs were given one week of acclimatization to 
observe their general health, to minimize  physiological 
stress and to ensure proper conduct of the study. 
After  acclimatization, hyperglycemia was induced 
as  previously described.19 Briefly,  animals were 
anesthetized and injected intravenously with 50 mg/kg 
sterile streptozotocin (STZ) solution in citrate  buffer 
(100 mM, pH 4.5; Sigma, St. Louis, MO, USA) 
for three consecutive days while control pigs were 
injected with equal amounts of vehicle (citrate buffer). 
During induction of  hyperglycemia, experimental 
pigs were fed normal chow  supplemented with dex-
trose (2× per day, 25 g, Sigma, St. Louis, MO, USA) 
to offset the anticipated insulin release. Afterwards 
they were fed a 10% high fat, 1.5% high cholesterol 
diet (Harlan Tekland, Madison, WI, USA) to mimic 
diabetic hyperlipidemia. The control pigs remained on 
a normal chow diet throughout the whole time of the 
experiment. One of the six experimental pigs required 
treatment with insulin glargine (0.2 mg/kg, Sanofi-
Aventis, Bridgewater, NJ, USA) subcutaneously once 
daily to prevent  recurrent  diabetic ketoacidosis for 
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the last 12 weeks of the  experiment. At  administered 
doses of insulin, blood glucose  levels were  maintained 
at  hyperglycemic  values above 20 mmol/l until 
 sacrifice. Due to the space limits, control animals 
were  sacrificed four weeks before diabetic animals. 
The  experimental pigs were sacrificed 6 months after 
induction of  hyperglycemia. All animal  procedures 
were  performed in accordance with the Principles of 
Laboratory Animal Care (NIH publication no. 85-23, 
rev. 1985) and were approved by the Columbia 
 University Institutional Animal Care and Use 
Committee.
Physiological status and general health 
condition evaluation
Plasma glucose levels were measured prior to the 
experiment initiation, 7 days after the first STZ 
 injection and then once per month for the duration 
of the experiment using a hand-held glucometer. 
 Glucose levels were monitored monthly until the end 
of the experiment or when indicated by a change in 
the clinical status of the pig. To assess  physiological 
status and to evaluate the general condition of 
 animals, weight measurement and routine blood tests 
for hemoglobin, blood urea nitrogen (BUN), gamma 
glutamyl transferase (GGT), creatinine, cholesterol 
and triglyceride were performed on the initial day of 
the experiment, and at 4, 8, 12 and 24 weeks after 
hyperglycemia induction.
Methyl-glyoxal (Mg) measurement
Extracts of sciatic nerve (50–70 mg) from control 
and hyperglycemic animals were collected on the 
final day of the experiment, digested with  perchloric 
acid (0.5 M) and the neutralized supernatant was 
 derivatized to 2-methylquinoxaline (MQ, 1:1) as 
 previously described.20 Levels of MG were then 
 indirectly measured by determining the levels of MQ 
by HPLC at 335 nm.
Age measurement
Establishment of  AGE baseline level was  conducted 
on the day of experiment initiation and blood AGE 
levels were measured 3 and 6 months after the 
 hyperglycemia induction. Briefly, samples were 
 prepared according to standard protocol,21  transferred 
onto 96 well plates, blocked for 1 h at room  temperature 
in blocking buffer (5% GSA, 1% BSA in 0.1 M PBS, 
pH 7.4) and  incubated for 3 h at room temperature 
with an  affinity-purified chicken antibody against 
AGEs diluted 1:100 in blocking buffer.22 After  primary 
 antibody incubation, samples were washed several 
times with PBS and subsequently incubated with goat 
anti-chicken IgG at 1:10,000 dilution in  blocking 
buffer, developed and read by  spectrophotometer at 
490 nm. Results were given in arbitrary AGE units 
(AAU), as previously described.21
Morphological analysis of peripheral 
nerve changes
Animals were euthanized by intravenous pentobar-
bital injections (Euthasol, 120 mg/kg, Henry Schein, 
Melville, NY, USA). A longitudinal skin  incision 
at the upper hindlimb level with blunt separation 
of  gluteal muscles was performed to expose the 
 sciatic nerve and 10 mm long nerve fragments were 
 collected. After collection, samples were immedi-
ately transferred to fixative (2.5% glutaraldehyde 
and 2%  paraformaldehyde (PFA) in 0.1 M PBS, 
pH 7.4) and stored at 4 °C until further processing. 
For  morphological analysis, samples were postfixed 
in 1% osmium tetroxide (0.1 M Phosphate Buffer), 
dehydrated with serial washing in ethanol (50%, 
75%, 95% -2 × 10 min and 100% -3 × 10 min), 
infiltrated with propylene oxide (1–2 hr) and embed-
ded in low viscosity epoxy medium (Spurr, Electron 
Microscopy Sciences, Hatfield, PA, USA). Cross 
sections were cut at 0.5 µm thickness using a 2088 
ultratome (LKB Produkter AB, Bromma, Sweden), 
stained with toluidine blue and examined with 
an Axioscope 2 Plus microscope (Zeiss, Thorn-
wood, NY, USA). Images were captured using the 
 Axiovision computer analysis system (Zeiss, Thorn-
wood, NY, USA) connected to CCD Axiocam video 
camera. The myelinated fiber density  quantification 
was performed using ImageJ 7.1 (NIH open source 
software, USA) with Cell Counter plug-in. One cross 
section of sciatic nerve fascicule from five control 
and five diabetic animals was analyzed. Within one 
cross section, three fascicles, largest, medium and 
the smallest, fitting into 400 × 400 µm square, were 
selected for quantification to ensure proper counting 
methodology.23–25 Discrimination between small 
(3.3–3.7 µm Ø) and large (11.2–21.6 µm Ø) fibers 
was set manually and standardized in all studied 
samples.
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Immunofluorescence (IF)
Sciatic nerve samples from diabetic and control animals 
(euthanasia procedure as previously described) were 
collected, transferred to fixative (4% PFA in destilled 
H2O) for 12 h, cryoprotected in 20% sucrose  solution 
for 24 h, mounted in optimal cutting  temperature 
compound (Tissue-Tek O.C.T., Sakura Finetek, 
 Zoeterwoude, Netherlands) and stored at -20 °C for 
further processing. Alternatively,  collected  samples 
were immediately snap- frozen in liquid  nitrogen 
and stored in -80 °C without prior fixation.  Frozen 
samples were cut transversely and longitudinally 
at 10 µm thickness on a cryostat (Microm HM 550, 
Thermo Scientific, Waltham, MA, USA) and  collected 
on polylysine coated slides (SuperFrost Plus, Fisher 
Scientific,  Pittsburgh, PA, USA), always in the same 
order—1st series with two diabetic and two control 
sections from 4 different animals in total and 2nd series 
with 4  sections (control or diabetic) from 1 animal, to 
ensure similar staining condition and to minimize risk 
of false  positive or false  negative results. After slide 
collection, PFA-fixed sections were allowed to dry for 
30 min at room temperature, while non-fixed sections 
were first transferred into containers with cold acetone, 
fixed for 5 min and then similar to PFA sections, and 
then they were allowed to dry for 30 min. Afterwards, 
all tissue sections were processed according to stan-
dard  immunostaining protocol. In brief, dried sections 
were incubated with blocking solution (Cas-block, 
 Invitrogen, Carlsbad, CA, USA) for 1 h, incubated in 
primary antibodies for 16 hours (for details, see anti-
body section), rinsed 4 × 5 min in PBS, incubated with 
secondary antibodies for 1 h, rinsed again for 4 × 5 min 
in PBS and mounted in fluorescent mounting medium 
(DAKO, Carpinteria, CA, USA). Mounted sections 
were allowed to stabilize for 30 min and afterwards 
were examined at 200x and 400x using a Scanning 
 Confocal System  (Bio-Rad  Radiance 2000, Zeiss, 
Thornwood, NY, USA) attached to Nikon Eclipse 800 
with  krypton-argon and red diode lasers  (excitation 
lines 488, 568, and 637 nm). Double  immunostained 
images were acquired in a  sequential mode to avoid 
bleed-through effect. All image  acquisition  parameters 
were kept identical for each studied specimen. To 
optimize the specificity of the labeling, the concentra-
tion of each primary antibody was tested in trial series 
ranging from 1:50 to 1:500 and the  optimal  dilution 
was used for experimental staining. To establish the 
 specificity of the secondary antibodies, standard 
 immunostaining procedure with omission or replace-
ment of primary antibodies on sections from each 
sample was  carried out parallel to the experimental 
staining. Quantification of immunofluorescent signal 
from control and hyperglycemic tissues single stained 
for RAGE and its ligands CML and S100B was cal-
culated using ImageJ histogram function for RGB 
images and obtained as mean grey value of pixels per 
selected region of interest26 given in arbitrary units 
(IAU). Colocalization percentage of RAGE positive 
fibers double stained for ligands and markers was cal-
culated manually using ImageJ Cell Counter Plugin, 
where number of RAGE positive fibers was used as a 
reference number (100% of all positive fibers).
The following primary antibodies were used: 
 polyclonal rabbit anti-RAGE and polyclonal 
 anti-S100B generated as described earlier (Ma et al 
2007), polyclonal goat anti-RAGE, 1:200  (GeneTex, 
Irvine, CA, USA); polyclonal rabbit anti- Vesicular 
Acetylocholine Transporter (VAChT), 1:500,  rabbit 
anti-Tyrosine Hydroxylase (TH), 1:200, rabbit 
 anti-Calcitonin Gene Related Peptide (CGRP), 1:200, 
monoclonal mouse anti-Macrophage Marker (MM, 
25F9)—86 kD cell surface and  cytoplasmic protein 
of mature human macrophages, 1:100 (Santa Cruz 
 Biotechnology, Santa Cruz, CA, USA);  polyclonal 
rabbit anti-Neurofilament (NF), 1:400 and  polyclonal 
affinity purified anti-Munc13-1, 1:400  (Synaptic 
 Systems, Goettingen, Germany. The  following 
 secondary antibodies were used: chicken anti-goat 
Alexa 568, 1:300, chicken anti-rabbit Alexa 488, 
1:200 and Alexa 568, 1:300 and rabbit  anti-mouse 
Alexa 488, 1:200 (Invitrogen, Carlsbad, CA, USA).
statistics
Statistical analysis was performed using SPPS 13 
(SPPS Inc., Chicago, IL, USA) or GraphPad, InStat 
(GraphPad Software, Inc., La Jolla, CA, USA). All 
values are presented as mean ± SEM. The statistical 
significance of differences was evaluated by ANOVA 
or Student’s t-test as defined in the text.
Results
Plasma glucose level
The baseline plasma glucose level in animals mea-
sured before STZ treatment and the development of 
 hyperglycemia was within standard  reference  values for 
rAge in the porcine hyperglycemic sciatic nerve
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the pig (2.91 ± 0.16 mmol/l). The  significant 5.4 -fold 
(15.62 ± 0.87 mmol/l) increase in glucose level was 
already observed on the 7th day after STZ injection, 
followed by 7.8 fold increase (22.76 ± 1.27 mmol/l) 
1 month after the injection. Monthly measurements per-
formed until the final day of sacrifice revealed  sustained, 
high levels of plasma glucose in the range of 22.6–
25.42 mmol/l (Table 1). ANOVA and  post-hoc Tukey-
Kramer analysis revealed statistical significance between 
baseline and all further data point values (P , 0.001).
Physiological status and routine 
laboratory diagnostic marker evaluation
Routine health examination did not show any 
 abnormalities throughout the entire period of the experi-
ment. The initial weight of the experimental pigs was 
19.73 ± 0.87 kg, increasing over the course of the 
experiment to a peak weight at 4 months of diabetes 
(27.6 ± 4.8 kg). Body weight subsequently declined to 
20.4 ± 3.08 kg by the end of the  experiment.  Levels of 
Hb and BUN remained within normal reference  values 
at all given time points, however there was a  statistically 
significant progressive decline of Hb  values over the 
duration of experiment (ANOVA, post-hoc Tukey-
Kramer test, P , 0.005). Creatinine levels were slightly 
below reference values, but no statistical difference was 
noted between baseline and given data points. Addi-
tionally, there was a trend toward an increase in the 
levels of GGT and  Triglyceride over the course of the 
experiment.  Furthermore,  significant increases in LDL 
and  Cholesterol, between baseline and 3-month values 
were noted (ANOVA, post-hoc Tukey-Kramer test, 
P , 0.005) and for HDL between baseline and all studied 
time points. Diagnostic marker values for control animals 
remained within standard reference range throughout the 
entire duration of the experiment (Table 1).
Tissue Methyl-glyoxal and Plasma Age 
measurement
HPLC analysis of sciatic nerve tissue revealed a low 
level of MG in control sciatic nerve tissue, ranging 
from 0.171 to 0.226 µm/g while in hyperglycemic 
sciatic nerve MG levels were ~22 fold higher (range, 
2.98-5.33 µm/g reaching statistical significance 
(ANOVA, post-hoc Tukey-Kramer test, P , 0.05) 
(Fig. 1A). As MGs are pre-AGE species, we exam-
ined levels of circulating AGEs in the plasma of dia-
betic animals and observed a trend toward a gradual 
increase in plasma AGE levels in the diabetic pigs. 
The baseline plasma AGE level was established prior 
to the experiment, estimated as 57.55 ± 5.82 AAU. 
At 3 months after STZ injection, plasma AGE 
level reached 75.33 ± 24.34 AAU, and at 6 months 
118.45 ± 50.35 AAU (~2 fold increase) (Fig. 1B).
Morphological analysis  
of peripheral nerves
Noticeable loss of small diameter myelinated fibers 
and some morphological changes were observed in 
sciatic nerve structure of diabetic animals (Fig. 2B, A 
Table 1. hematological and biochemical parameters were measured to assess physiological status of diabetic animals. 
similarly to human diabetic patients, pigs with hyperglycemia also exhibit hyperlipidemia. Detailed statistical analysis in 
Material and Method section.
substance Initial 
(pre-sTZ)
1 month 2 months 3 months Reference 
values* 
glucose (mmol/l) 2.91 ± 0.16 22.76 ± 1.27 22.6 ± 1.27 24.01 ± 1.34 1.50–3.5
hemoglobin (mmol/l) 6.79 ± 0.25 5.70 ± 0.19 5.74 ± 0.09 5.85 ± 0.13 5.5–10.4
BUn (mmol/l) 2.59 ± 0.42 5.96 ± 0.69 6.74 ± 6.74 6.19 ± 1.26 0.70–7.85
creatinine (µmol/l) 53.04 ± 9.72 54.80 ± 3.27 67.18 ± 9.72 74.26 ± 13.23 106–180
ggT (U/l) 47.33 ± 6.5 61.16 ± 1.9 71.5 ± 13.56 69.5 ± 10.72 14–34 
cholesterol (mmol/l) 2.73 ± 0.14 6.35 ± 1.31 6.95 ± 1.54 8.96 ± 1.54 1.3–2.6
Triglyceride (mmol/l) 0.65 ± 0.14 1.19 ± 0.48 2.33 ± 0.88 2.85 ± 1.17 0.2–0.65
LDL (mmol/l) 1.56 ± 0.22 3.72 ± 1.12 4.47 ± 1.156 5.03 ± 1.11 0.6–2
hDLD (mmol/l) 0.87 ± 0.11 2.29 ± 0.13 2.37 ± 0.14 2.51 ± 0.03 0.6–2
*swindel M. Appendix. hematology and serum chemistry. In: swindel M, Swine in the laboratory: Surgery, Anaesthesia, Imaging and Experimental 
Techniques. 2nd ED, crc Press; 2007:409 Bollen PJ. hansen AK, rasmusen hJ. Important Biological Features. normative Values. In: The laboratory 
swine. crc Press, 2000: 14. Winnicka A. Reference Values of common laboratory tests in veterinary medicine (In Polish). Warszawa, Poland. Wydawnictwo 
sggW. 1997 holevet et al. Arterioscler Thromb Vasc Biol. 1998;18:415–22 (and references within).
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respectively). The overall density of  myelinated fibers of 
 diabetic pigs was lower compared to the control group 
(Fig. 2D, C respectively). The nerve morphology was 
evaluated based on the size of fiber diameter. The num-
ber of large diameter myelinated nerve fibers was similar 
between both groups (control, 898.54 ± 70.57 per mm 
vs. hyperglycemic, 1,001.04 ± 113.49 per mm). How-
ever, the number of small diameter myelinated fibers 
was significantly lower (~19%) in hyperglycemic sam-
ples (control 332.29 ± 19.83 vs. diabetic 260.62 ± 22.42 
per mm; Paired T-test, P , 0.05) (Fig. 2E).
Immunofluorescence
Assessment of single staining immunofluorescence 
signal revealed changes in  immunohistochemical 
expression for RAGE (Fig. 3A, B) and one of 
its ligands, S100B (Fig. 3E, F), whereas CML 
(Fig. 3C, D) remained consistent between control 
and  hyperglycemic nerve samples. Furthermore, 
 quantification of double-stained fibers positive both for 
RAGE and marker proteins NF (Fig. 4A, B), VAChT 
(Fig. 5A, B), TH (Fig. 5C, D), CGRP (Fig. 5E, F), 
CML (Fig. 6A, B) and S100B (Fig. 6C, D) revealed 
variable colocalization patterns depending on the 
protein studied, demonstrating significantly higher 
number of RAGE positive fibers co-stained for NF 
(91% ± 5%, Fig. 4C), and lower number co-stained 
for TH (58% ± 2%, Fig. 5H), CGRP (42% ± 4%, 
Fig. 5I) and S100B (82% ± 12%, Fig. 6H) compared 
to the control animals. (paired T-test, P , 0.05). 
Macrophage Marker (MM) staining revealed a lack 
of macrophage positive signal in the control group, 
but distinct well defined perineurium staining in the 
diabetic group (Fig. 6E, F).
Discussion
Our study demonstrates that the porcine sciatic nerve 
after 6 months of sustained hyperglycemia exhibits 
alterations in fiber density often observed in human 
patients with long-term diabetes. In addition, the 
results of our study provide for the first time the pre-
liminary evidence of the expression of RAGE and its 
ligands in the porcine peripheral nerves and provide 
insight into MG, AGE precursor, and AGE levels in 
nerve and circulating blood, respectively, of healthy 
and STZ-injected pigs. Expression of the studied pro-
teins as well as the level of neural MG is noticeably 
higher in hyperglycemic tissues and an increased 
trend in plasma AGE level is observed during the 
course of disease. Furthermore, the results of the 
routine  laboratory plasma lipid tests were consistent 
with the data obtained from human subjects, suggest-
ing, as shown recently in hyperglycemic patients 
with diagnosed peripheral neuropathy, that elevated 
levels of plasma lipids correlate with progression of 
neurological changes and neuropathy under diabetic/
hyperglycemic conditions.27,28 The alteration of fiber 
density and morphology and significant loss of the 
small diameter fibers in the peripheral sciatic nerve 
are  characteristic morphological signs of progressive 
neuropathy in human diabetic patients,29,30 Until now, 
the data on early structural changes in the peripheral 
nerve of  hyperglycemic/diabetic  animals was by far 
limited to the studies on small animal models and 
 therefore almost by definition redundant as compared 
to  studies on larger, closer genetically, anatomically 
and  physiologically related species, often failing to 
 replicate subtle, sub-clinical  metabolic,  biochemical 
and/or morphological changes.31,32 As shown in 







































Figure 1. A) Methyl-glyoxal levels in sciatic nerve tissue. sciatic nerve tis-
sue was retrieved and subjected to hPLc analysis for detection of  levels 
of pre-Age methyl-glyoxal (Mg). As shown, hyperglycemic animals had 
significantly higher level of MG compared to the controls, *P , 0.05. 
B) Plasma Age levels. Age levels were measured by eLIsA in the 
plasma and compared with the baseline level to determine the degree of 
glycation occurring during sustained hyperglycemia.
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structural  deficits and  symptomatic manifestation of 
the  developing neurological abnormalities are less 
 prominent and often delayed, as compared to human 
subjects at the  relative stage of the disease, thus fail 
to serve as a probe of early DBN  manifestation.33 
 Strikingly, in the same pig model investigations on 
retinal  morphological  aberrations revealed that, 
in  correlation with our data, 6 months of sustained 
 hyperglycemia results in basement  membrane 
 thickening further  supporting the notion that the STZ-
induced pig model might be a useful tool aimed at 
capturing early signs of  metabolic and morphological 
disturbances evoked by chronically elevated level of 
glucose. It has been well  established that sustained 
elevations of blood  glucose levels affect and alter 
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Figure 2. A, B) sciatic nerve morphometry. semi-thin toluidine blue sections prepared from control pig sciatic nerve reveal a dense network of large 
diameter myelinated fibers motor and small diameter myelinated sensory regularly-shaped fibers, whereas sections from a hyperglycemic sciatic nerve 
reveal  visible loss of small fibers; overall fiber morphology is altered suggesting the onset of sensorimotor neuropathy. c, D) Lower panel images magnify 
nerve morphology, displaying large and small fibers in the control sections and indicating increase in the number of irregular shaped fibers (asterisks) in 
the diabetic nerve. e) Quantification of fiber number was performed on the indicated sections and reported as values per mm. *P , 0.05.
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to the peripheral  nervous system malfunctions. 
 Hyperglycemia-induced oxidative stress and the sub-
sequent increase in free radical production leads to 
cellular dysfunction and neuronal cell loss both via 
activation of apoptosis or necrotic cell death. As 
reported in human studies, sensory and/or autonomic 
fibers are usually affected early in diabetic patients.30 
Very late evidence of sensory fiber dysfunction may be 
detected by standard neurological examination com-
bined with physiological tests, but early onset of sen-
sory dysfunction might be easily overlooked and/or 
masked by other symptoms of diabetes until patients 
develop severe, painful neuropathy, as pointed out in 
an earlier report.34 Our morphological studies revealed 
a significant ~19% loss of small diameter fibers in the 
sciatic nerve at 6 months of hyperglycemia, which is 
the first detection of such loss reported to date in the 
peripheral nervous system in a large animal model. 
Similarly, a loss of cardiac nerve fibers was observed 
 electrophysiologically in hyperglycemic pigs.18 Our 
study supports the notion that observable loss of nerve 
fibers might be also influenced by the dietary regimen 
and hyperlipidemia, as reported in studies on obese 
human subjects35 and observed in alimentary diabetes 
models in rodents.36,37
In addition to the morphological findings, our 
immunohistochemical studies demonstrate  differential 
expression of RAGE and its two ligands in peripheral 
nerve tissue, previously not reported in this species and 
tissue. As observed in single and double  staining images, 
RAGE  immunofluorescence was more  prominent in the 
hyperglycemic  samples, present not only in the nerve 
itself but also in the surrounding vessels. Its expression 
in relation to neuronal marker, Neurofilament expressed 
by all fibers, revealed that in the control/healthy nerve 
 tissue RAGE presence is confined rather to supportive 
cells than nerve fibers however as the co- staining with 















































































Figure 3. Assessment of immunofluorescent signal in sciatic nerve sections single stained for RAGE and its ligands. Difference in immunofluorescent 
signal between control and hyperglycemic tissues was observed for rAge (A, B) and s100B (e, F) indicating that under hyperglycemic conditions immu-
noexpression of these two proteins is increased. Level of cML (c, D) immunofluorescent signal was relatively low in both groups of animals and did not 
reach significant difference, however visible increase of CML positive fibers was noticed in hyperglycemic nerves suggesting that hyperglycemia likely 
induces immunoexpression changes of AGEs in the peripheral nerve over long period of time. *P , 0.05.
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might be also detected in few motor, sensory or auto-
nomic fibers.  Hyperglycemic tissue staining revealed 
an increased presence of RAGE in all types of fibers 
and blood vessels which is consistent with previous 
reports on RAGE in murine diabetic tissues. RAGE, 
commonly linked and often cited as a molecule medi-
ating and aggravating complications occurring in 
 hyperglycemic states and inflammation disorders,9 dis-
played increased  expression levels based on immuno-
histochemical staining evaluation in the hyperglycemic 
vs.  control nerve samples. It is well known that in sev-
eral  pathological states such as diabetes,  atherosclerosis 
and neurodegenerative diseases, RAGE  expression is 
elevated in response to the increased level of newly 
forming AGEs and other ligands.9 Until now, increased 




















Figure 4. Neuronal RAGE staining. Confocal images of double immunostaining of RAGE (red) with the neuronal marker, Neurofilament (NF, green). 
colocalization of rAge and nF is very low in the control tissue (A), but it is observed in the diabetic tissue (B), suggesting that rAge presence might 
be largely limited to Schwann cells in sciatic nerves of healthy animals but it is localized to nerve fibers in the hyperglycemic animals. As expected under 
hyperglycemic conditions, an increase in rAge staining is not only observed in the nerve but also in surrounding blood vessels (B). The quantitative 
analysis of the colocalization pattern revealed significant difference in number of RAGE positive fibers co-stained for NF between control and hypergly-
cemic animals (c). *P , 0.03.
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has not been shown. Taking into account available data 
obtained from our  previous rodent studies and our cur-
rent  findings, a possible RAGE—ligand interaction 
metabolic pathway in diabetic neuropathy might be 
suggested. Briefly, RAGE-ligand interaction through 
intermediate  signal transduction processes such as 
NF-KB and MAP kinase pathways
38,39 may lead to 
increased cellular oxidative stress and thus contribute 
to nerve cell damage and dysfunction. Furthermore, 
it has been shown that genetic deletion of RAGE in 
mice correlates with lower expression of NF-KB in sen-
sory dorsal root ganglia (DRG) neurons, as well as in 
sensory sural nerve fibers.34,40
Interestingly, RAGE co-localization with its two 
ligands, CML and S100B, revealed that in  control 















































































Figure 5. Immunofluorescence analysis of RAGE distribution in different types of sciatic nerve fibers. control and diabetic sciatic nerve tissues were sub-
jected to rAge (red) co-immunostaining with VAchT (motor neuron marker, A, B, green), Th (autonomic neuron marker, c, D, green) and cgrP (sensory 
neuron marker, e, F, green). Overlay images show that RAGE is localized in all types of sciatic nerve fibers. Note that the perineurial immunofluorescence 
was non-specific as observed in control staining with the secondary antibody alone. The quantitative analysis of the colocalization pattern revealed that 
although the number of double stained RAGE/VAChT positive fibers was similar in both groups of animals, there was a significantly lower number of 
RAGE/TH and RAGE/CGRP positive fibers between control and diabetic animals (G, H, I), supporting our earlier morphological findings on autonomic and 
sensory fiber loss in diabetic nerve. *P , 0.001.
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 co- localization indicating that under physiological 
 conditions, RAGE and its ligands are expressed at 
baseline levels in a limited numbers of nerve fibers 
and most likely interact with each other,  producing 
RAGE-ligand complexes. In hyperglycemic  tissue, 
there is a  relevant increase in both CML and 
S100B expression,  however the absolute value of 
co- localization of these two proteins with RAGE 
decreases,  suggesting that both RAGE and its ligands 
may interact with other proteins as well. CML, one 
of the advanced  glycation products and a biomarker 
of oxidative stress, accumulates at the higher rate 
in  diabetes contributing along with other AGEs 
to the development of diabetes complications.41 
 Furthermore, a recent report on CML showed that 
its accumulation is increased in aqueous humor of 
retina in diabetic patients and this increase  correlates 
with the  progression of retinopathy in those patients42 
 suggesting, as observed in our study, that similar cor-
























































Figure 6. colocalization of rAge and its ligands s100B and cML and rAge co-expression with macrophage marker (MM). sciatic nerve sections from 
control and diabetic animals were subjected to rAge (red) co-immunostaining with cML (carboxymethyl Lysine, A, B, green), s100B (ligand/schwann 
cell marker, c, D, green), MM (macrophage marker, e, F, green). The quantitative analysis of the colocalization pattern revealed that there was a 
 significant difference in number of RAGE/S100B positive fibers between control and hyperglycemic animals (G, H). *P , 0.001.
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S100B has been demonstrated to exert, in nanomolar 
concentrations, a positive effect on axonal outgrowth, 
neuronal  differentiation and survival during devel-
opment and injury of  peripheral nerves. However, 
higher micromolar concentrations of this protein and 
its binding to RAGE leads to neurotoxicity resulting 
in neuronal cell apoptosis, production of free radicals 
and caspase cascade activation in cultured cells.43 
S100B, apart from interacting with RAGE, has mul-
tiple binding domains through which it is able to 
interfere with cytoskeletal molecules and hence it 
may play an important role in events occurring at 
the axonal endings in normal and pathological con-
ditions such as acute/chronic injury or neurodegen-
erative disorders.44 Furthemore, increased observed 
macrophage positive cells around the hyperglyce-
mic neural tissue confirmed an inflammatory status 
of hyperglycemic peripheral nerve suggesting the 
influence of RAGE on neuropathy from multiple 
sources.
In conclusion, our study addresses for the first 
time the state of the peripheral nerve in the hypergly-
cemic STZ-induced diabetic pig. Our results indicate 
that after 6 months of hyperglycemia,  morphological 
 aberrations of peripheral nerve fibers and  noticeable 
loss of the small diameter fibers occur in the pig and 
suggest that STZ-injected pigs might serve as a rele-
vant model in early studies of peripheral nerve changes 
under hyperglycemic conditions.  Furthermore, our 
data reveals that levels of pre-AGE, AGEs and RAGE 
are modulated in the peripheral nerve of the STZ-
injected pig in early-stage hyperglycemia. This find-
ing provides background for more detailed  studies on 
RAGE-ligand contribution to pathogenesis of periph-
eral nerve changes as well as reference data for fur-
ther, pre-clinical studies on hyperglycemia-related 
neuronal changes in the species more closely related 
to humans.
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